Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain

    SBC: Regulonix            Topic: NIDA

    ABSTRACT Chemotherapy induced peripheral neuropathyCIPNis a commonprevalenceand potentially doselimiting side effect of many cancer chemotherapy drug treatment regimensClinicallyCIPN presents with pain that is burningshooting or electric shock likeThe increase in prevalence of cancer coupled with an increase in the cancer survival rates due to chemotherapy regimens is transforming cancer pain into ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Fixed dose analgesic combination with non-opioid mechanism to prevent opioid misuse

    SBC: Synventa LLC            Topic: NIDA

    PROJECT SUMMARYABSTRACTWith nearlymln people suffering from chronic pain in the US alone and the global market projected to reach $bln bythere is both a major unmet medical need and a significant commercial opportunityDominated by opioid drugsthis field also suffered from alarming consequences of opioid drug overuse and misuseAntagonists acting at TRPVreceptor have long been recognized as one of t ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Novel formulations of Allopregnanolone to treat Alzheimer's Disease

    SBC: Proneurogen, Inc            Topic: NIA

    PROJECT SUMMARY ABSTRACT Alzheimer s diseaseADis a progressive multifactorial disease affecting more thanmillion people worldwide and is the most common dementia of late lifeTo dateno interventions have demonstrated substantial therapeutic efficacy to preventdelay or treat ADCurrent thinking in the field embraces the complexity of AD pathophysiologywhich has enabled a more diverse therapeutic pipe ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A Simple Blood Test for Microsatellite Instability Status

    SBC: CALVIRI, INC.            Topic: 102

    Abstract Immune checkpoint inhibitorICIimmunotherapeutics are having an important and expanding impact on the treatment of cancerAfter only a few years of clinical useICIs have become a multi billion dollar family of productsHoweveronlyof patients have a positive response to treatmentTo datethe best indicator for a positive response is the microsatellite instabilityMSIstatusIndividualsno matter wh ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. IF Conversion System for High-Bandwidth Multiplexed Sensors Arrays

    SBC: Alphacore, Inc.            Topic: None

    Alphacore will develop an Intermediate Frequency (IF) Conversion System for High-Bandwidth Multiplexed Sensors Arrays for Phase II of NIST's 2018 soliciation for Exploratory Measurement Science Topic 9.04.02.68.The proposing team has already successfully developed and evaluated a prototype board in Phase I.The goal in Phase II is therefore to achieve three primary objectives:1) Optimize the design ...

    SBIR Phase II 2019 Department of CommerceNational Institute of Standards and Technology
  6. SBIR Phase II: A tool for estimating objective outcome measures in clinical speech applications

    SBC: Aural Analytics, Inc.            Topic: SH

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to introduce a set of powerful neurological health metrics for objective and reliable tracking of patient outcomes, clinician performance, and therapy efficacy. Significant societal benefits may be realized from the introduction of this technology in the clinical applications and clinical ...

    SBIR Phase II 2019 National Science Foundation
  7. A badge-like exposure device for occupational safety and epidemiological study

    SBC: TF HEALTH CORPORATION            Topic: 113

    Abstract Chemical exposure poses a threat to the safety and health of each of usespecially those who work in certain industriessuch as petroleum extraction and refinery facilitiesmining industryand fertilizer factoriesVarious sensing technologies have been developed over the past decades to address the needbut a low cost and accurate personal exposure device that can track multiple chemical pollut ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. SBIR Phase I: SenixBand- Remote Independent-Living Monitor and Frailty Status Tracker for Older Adults

    SBC: BIOSENIX LLC            Topic: SH

    The broader impact of this Small Business Innovation Research (SBIR) Phase I project will revolutionize the way older adults who live independently at home are monitored. According to the American Association of Retired Persons (AARP), nearly 90% of older adults (age 65 and above) prefer to stay independently at their homes, coining the term "ageing in place". The proposed monitoring system monito ...

    SBIR Phase I 2019 National Science Foundation
  9. SBIR Phase I: Thin Silicon Solar Cells for Aerospace Applications

    SBC: REGHER SOLAR LLC            Topic: S

    The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to enable the emerging and rapidly growing markets of solar powered aerospace devices. The solar array is often the most expensive component of satellites, drones and airships and reducing their cost 10 times while also reducing the weight 5 times and making solar cells flexible can disrupt one of the main barr ...

    SBIR Phase I 2019 National Science Foundation
  10. Discovery of Novel Peptidic Inhibitors of the Non-Catalytic Function of Focal Adhesion Kinase (FAK)

    SBC: Faknostics, LLC            Topic: 102

    PROJECT SUMMARY ABSTRACT Focal Adhesion KinaseFAKis a major cancer drug target that is overexpressed in multiple tumor typesFAK is a critical regulator of tumor survivalinvasionproliferationmetastasisand immune evasionCurrent FAK inhibitors that target the ATP binding pocket of the kinase domain do no effectively inhibit FAK in cancer because FAK also functions as a scaffolding proteinThe Focal Ad ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government